Header Logo

Connection

Michael Cookson to Disease Progression

This is a "connection" page, showing publications Michael Cookson has written about Disease Progression.
Connection Strength

0.541
  1. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
    View in: PubMed
    Score: 0.131
  2. Castration-Resistant Prostate Cancer: An Algorithmic Approach. Urol Clin North Am. 2017 Nov; 44(4):647-655.
    View in: PubMed
    Score: 0.125
  3. Positive surgical margins at radical prostatectomy: much ado about nothing? Urol Oncol. 2013 Apr; 31(3):285-7.
    View in: PubMed
    Score: 0.091
  4. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
    View in: PubMed
    Score: 0.039
  5. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529.
    View in: PubMed
    Score: 0.036
  6. Transition from androgenic to neurosteroidal action of 5a-androstane-3a, 17ß-diol through the type A ?-aminobutyric acid receptor in prostate cancer progression. J Steroid Biochem Mol Biol. 2018 04; 178:89-98.
    View in: PubMed
    Score: 0.031
  7. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997 Jul; 158(1):62-7.
    View in: PubMed
    Score: 0.031
  8. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57.
    View in: PubMed
    Score: 0.022
  9. Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. BJU Int. 2012 Jan; 109(2):226-32.
    View in: PubMed
    Score: 0.020
  10. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials. 2007 Nov; 28(6):763-9.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.